Bioprosthetics Market Report 2025

The bioprosthetics market size has grown strongly in recent years. It will grow from $5.72 billion in 2024 to $6.27 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. Growth in the historic period was supported by the rising prevalence of cardiovascular diseases, increasing demand for minimally invasive surgeries, growth in the geriatric population, expansion of healthcare infrastructure, and greater adoption of tissue-based implants.

The bioprosthetics market size is expected to see strong growth in the next few years. It will grow to $8.95 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. Growth in the forecast period is expected to be driven by a stronger preference for personalized treatment solutions, higher healthcare spending in emerging economies, expansion of medical tourism, wider availability of advanced surgical facilities, and an increasing focus on patient-centered care. Key trends anticipated for the forecast period include technological progress in valve design, innovations in tissue preservation methods, advancements in minimally invasive implantation techniques, the development of biocompatible materials, and progress in regenerative medicine.

The growing prevalence of cardiovascular diseases is expected to drive the expansion of the bioprosthetics market in the coming years. Cardiovascular diseases encompass a range of disorders that affect the heart and blood vessels, including coronary artery disease, heart failure, arrhythmias, congenital heart defects, and cerebrovascular diseases such as stroke. The rise in cardiovascular conditions is partly attributed to poor dietary habits, including the consumption of foods high in saturated fats, salt, and sugar, which contribute to obesity, hypertension, and high cholesterol levels. Bioprosthetics play a crucial role in treating these conditions by replacing damaged heart valves or blood vessels with biologically compatible implants, thereby improving heart function and reducing the risk of complications. For example, the American Heart Association reported in January 2024 that cardiovascular-related deaths increased slightly to 931,578 in 2023, up from 928,741 in 2022. This rising incidence of cardiovascular diseases is a key factor driving the growth of the bioprosthetics market.

Key companies in the bioprosthetics market are focusing on the development of advanced tissue technologies. This technology involves specialized treatments of bioprosthetic materials to reduce calcification and improve their long-term functionality. For instance, in September 2022, Edwards Lifesciences Corporation, a U.S.-based medical device company, received FDA approval for the SAPIEN 3 Ultra RESILIA valve. This valve uses RESILIA tissue technology, which involves bovine pericardial tissue treated with anti-calcification technology to extend durability. The SAPIEN 3 Ultra RESILIA valve features a low-profile delivery system designed to simplify implantation and improve procedural precision. It is also the only dry storage transcatheter heart valve available in the U.S., offering ease of use and the potential to provide freedom from structural valve deterioration for up to five years, with the possibility of extended clinical benefits.

In July 2024, Edwards Lifesciences Corporation further expanded its structural heart portfolio by acquiring Innovalve Bio Medical Ltd., an Israel-based company specializing in bioprosthetics. The terms of the acquisition were not disclosed, but the deal is expected to accelerate product development, enhance clinical capabilities, and increase patient access to minimally invasive heart valve therapies, particularly in the field of transcatheter aortic valve replacement (TAVR).

Major players in the bioprosthetics market are Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, Meril Life Sciences Pvt. Ltd., LivaNova PLC, Artivion Inc., LifeNet Health Inc., TTK Healthcare Limited, Corcym S.r.l., Biosensors International Group Ltd., Braile Biomedica, Xeltis NV, Peijia Medical Technology Co. Ltd., Labcor Laboratórios Ltda., Colibri Heart Valve LLC, Autotissue Berlin GmbH, Humacyte Inc., Bioprosthetics Inc., and Shijiazhuang Perfect Prosthetic Manufacture Co. Ltd.

North America was the largest region in the bioprosthetics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bioprosthetics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bioprosthetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Bioprosthetics is a field of biomedical science focused on developing implants or devices made from biological materials, sometimes combined with synthetic components, to replace or support damaged or missing tissues in the body. These materials are designed to replicate the structure and function of natural tissue, ensuring compatibility with the body, lowering the risk of immune rejection, and maintaining durability and long-term performance.

The primary types of bioprosthetics are allograft, xenograft, and autograft. An allograft is a transplant of tissue or an organ taken from a donor of the same species who is genetically different from the recipient. Bioprosthetics are applied in areas such as cardiovascular care, orthopedics, wound healing, and other fields, and are utilized by end users including hospitals, specialty centers, and others.

The bioprosthetics market research report is one of a series of new reports that provides bioprosthetics market statistics, including the bioprosthetics industry global market size, regional shares, competitors with the bioprosthetics market share, detailed bioprosthetics market segments, market trends, and opportunities, and any further data you may need to thrive in the bioprosthetics industry. This bioprosthetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bioprosthetics market consists of revenues earned by entities by providing services such as custom implant design, biocompatibility testing, 3d modeling, and clinical research. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprosthetics market also includes sales of vascular grafts, cartilage repair scaffolds, bone grafts, dermal matrices, and biologic meshes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.